New Rochelle, NY, June 24, 2019--SHERLOCK technology is a new CRISPR-based platform that is rapid and portable and enables detection and quantitation of plant genes to support a variety of agricultural applications. Additional advantages, including the ability to process crude plant extracts with minimal nucleic acid sample preparation required are described in a research article published in The CRISPR Journal, a new peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Click here to read the full-text article free on The CRISPR Journal website through July 24, 2019.
Feng Zhang, from the Broad Institute of MIT and Harvard (Cambridge, MA) and Massachusetts Institute of Technology (Cambridge), and coauthors Omar Abudayyeh, Jonathan Gootenberg, and Max Kellner, from the Broad Institute, MIT, and Harvard Medical School (Boston, MA) present the recently developed nucleic acid detection system called SHERLOCK in the article entitled "Nucleic Acid Detection of Plant Genes Using CRISPR-Cas13." The platform overcomes many of the limitations of current nucleic acid detection systems and provides single-molecule sensitivity and single-nucleotide specificity with high multiplexing capability.
The paper describes how the refined CRISPR-based tool SHERLOCK was applied for the first time in plants. SHERLOCK has the potential to be an important tool in agriculture for the rapid detection of pathogens or pests and in plant breeding. SHERLOCK is easy to use, portable and field-ready, and low cost. It can generate a fluorescent or colorimetric readout when Cas13 recognizes the target nucleic acid sequence.
Rodolphe Barrangou, PhD, Editor-in-Chief of The CRISPR Journal states: "This is a great example of the expansion of CRISPR-based technologies beyond genome editing per se, with the use of novel Cas molecular machines for the flexible detection of DNA sequences of interest. The applications extend beyond diagnostics and the authors show here how this can be broadly applied in agriculture."
Research reported in this publication was supported by the National Institutes of Health under Award Numbers 1F30-CA210382, 1R01-HG009761, 1R01-MH110049, and 1DP1-HL141201. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
About the Journal
The CRISPR Journal is a groundbreaking peer-reviewed journal dedicated to outstanding research and commentary on all aspects of CRISPR and gene editing research. Published bimonthly in print and online and led by Editor-in-Chief Rodolphe Barrangou, PhD, North Carolina State University, the Journal covers CRISPR biology, technology and genome editing, and commentary and debate of key policy, regulatory, and ethical issues affecting the field. For complete information and a sample issue, please visit The CRISPR Journal website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Human Gene Therapy, ASSAY and Drug Development Technologies, Nucleic Acid Therapeutics, Stem Cells and Development, and Biopreservation and Biobanking. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.
Mary Ann Liebert, Inc. 140 Huguenot St., New Rochelle, NY 10801-5215 http://www.liebertpub.com Phone: (914) 740-2100 (800) M-LIEBERT Fax: (914) 740-2101
The CRISPR Journal